Both cancers were hypermutated with mutational signatures of MMR deficiency14,15 (Fig.1 e, f), loss of PMS2 expression on immunohistochemistry (IHC) and high exomic MSI burden (colon: 207; PDHGG: 1360; median for MMR-proficient controls: 17). Here, PMS2 is linked to cancer.